A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a ...

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment November 18, 2024 — 08:59 am EST Written by TipRanks Auto-Generated Newsdesk for TipRanks -> ...

The Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in narcolepsy was supported by the positive results from the Phase 2 CONCERT study, a randomized, double-blind ...

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment TipRanks Nov. 18, 2024, 07:59 AM ...